Safe and effective use of combination antiretroviral treatment

Acta Clinica Belgica

Volumn 54, Issue 2, 1999, Pages 55-60

  Colebunders, R ^a   Clumeck, N ^b   Florence, E ^a   Vandercam, B ^c   Van Wanzeele, F ^d   Van Wijngaerden, E ^e   Lacor, P ^f   Demonty, J ^g   De Wit, S ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antiretroviral treatment; Efficacy; HIV infection; Safety

Indexed keywords

AMPHOTERICIN B; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; INDINAVIR; ISONIAZID; ITRACONAZOLE; NELFINAVIR; NEUROLEPTIC AGENT; PENTAMIDINE; PROTEINASE INHIBITOR; PYRIMETHAMINE; QUINOLONE DERIVATIVE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SEDATIVE AGENT; STAVUDINE; SULFADIAZINE; TETRACYCLINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

BLOOD TOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; NEUROTOXICITY; PRACTICE GUIDELINE; REVIEW; TREATMENT FAILURE; VIRUS LOAD;

EID: 0033051586     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1999.11754209     Document Type: Review

References (30)

1. Torres RA, Barr M. Impact of combination therapy for HIV infection on in patient census. N Engl J Med 1997; 21: 1531-2.
2. th World AIDS Conference Geneva, Abstract 12223.
3. BHIVA Guidelines Co-ordinating Committee: British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-6.
4. Carpenter ChCJ, Fischl MA, Hammer SM, et al. Antiretroviral Therapy for HIV Infection in 1997. JAMA 1998; 280 (1): 78-86.
5. Centers for Disease Control and Prevention, Report of the NIH Panel to define principles of therapy of HIV infection and Guidelines for the use of Antiretroviral Agents in HIV-infected adults and adolescents. MMWR 1998; 47: 1-82.
6. Hammer SM, Yeni P. Antiretroviral therapy: where are we? AIDS 1998; 12: S181-S188.
7. Carpenter ChCJ, Fischl MA, Hammer SM, et al. Antiretroviral Therapy for HIV Infection in 1998. JAMA 1998; 280 (1): 78-86.
8. Carpenter C, Feinberg M, et al. Report of the NIH Panel to define principles of therapy of HIV infection. Ann Int Med 1998; 128: 1057-1078.
9. Fauci AS, Bartlett JG, et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Int Med 1998; 128: 1079-1100.
10. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
11. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. The Lancet 1998; 351: 1328.
12. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retroviral 1995; 10: S28-S33.
13. Chun TW, Struyver L, Mizell SB, et al. Presence of an inducable HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193-7.
14. Pantaleo G, Perrin L. Can HIV be eradicated. AIDS 1998; 12 (suppl A): S175-S180.
15. Raboud JM, Montaner JSG, Conway B, et al. Variation in plasma RNA levels, CD4 cell count and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 1996; 174; 191-4.
16. Styrt BA, Piazza-Hepp TD, Chikami GK. Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Res 1996; 31: 121-135.
17. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92.
18. Colebunders R, De Droogh E, Pelgrom Y, Depraetere K, De Jonghe P. Painful hyperaesthesia caused by protease inhibitors? Infection 1998; 26: 250-1.
19. Brichacek B, Swindells S, Janoff EN, Pirrucello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal medicine. J Infect Dis 1996; 174: 1191-9.
20. Havlir DV, Lange JMA. New antiretrovirals and new combinations. AIDS 1998; 12 (suppl A): S165-S174.
21. De Clercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with whicht they interact. Adv Virus Res 1993; 42: 1-55.
22. Hertoghs K., M. Conant, P. Schel, A. et al. The RT-Antivirogram: a rapid method to determine phenotypic (multi) drug resistance in plasma of patients treated with various HIV-1 RT inhibitors. Antivir Ther 1 (Suppl. 1): 40.
23. De Wolf F, De Jong JJ, Hertogs K, Danner SA, Lange JMA, Goudsmit J. Virologische evaluatie van behandeling van HIV-geïnfecteerden met (combinaties van) antiretrovirale middelen in het Academisch Medisch Centrum Amsterdam, 1996/97. Ned Tijdschr Geneeskd 1998; 142 (11): 573-8.
24. Taburet AM, Singlas E. Drug Interactions with Antiviral Drugs. Clin Pharmacol 1996; 30 (5): 385-401.
25. Centers for Disease Control and Prevention. Clinical Update. Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 1996; 45: 921-925.
26. Morris LS, Schulz RM. Patient compliance - an overview. J Clin Pharm Ther 1992; 17: 283-95.
27. Anderson RJ, Kirk LM. Methods of improving patients compliance in chronic disease states. Arch Intern Med 1982; 142: 1673-5.
28. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665-70.
29. Singh N, Squier C, Sivek C, Wagener M, Hong Nguyen M, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 3: 261-9.
30. th World AIDS Conference Geneva, Abstract 42430.